 I. To evaluate the safety and tolerability of ipilimumab part 1 or ipilimumab plus nivolumab part 2 following lead-in of v-raf murine sarcoma viral oncogene homolog B1 BRAF and mitogen-activated protein kinase kinase MEK inhibitors, either alone or in combination, in patients with BRAFV600 mutant melanoma. 